SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has announced the appointment of Jim Daly, as the latest addition to its board of directors. Mr. Daly has 30-years of experience under his belt, as a biopharmaceutical executive. The CEO of Halozyme, Dr. Helen Torley, highlighted that Daly would serve as an important resource, in the commercialization of the company’s PEGPH20 drug. She also expressed her pleasure at having Daly on board.

Before moving to Halozyme, Mr. Daly was the EVP at Incyte Corporation, from 2012 to 2015. He also has prior experience working with Amgen, as Senior VP of North America commercial operations and global marketing and commercial development. Furthermore, Daly is also known to have started his career at GSK, where he held multiple positions, with varying responsibilities.

Halozyme is also expected to present at the 36th Annual Cowen & Company Healthcare conference, in Boston, on March 9. Added to this, the company has also announced that it would be present at the Barclays Capital Global Healthcare Conference, in Miami, on March 15. HALO would be represented by CFO, Laurie Stelzer, at both conferences.

The company had also filed its 4Q2015 financial results, reporting net earnings of $4.32 million. HALO also reported the widening of its gross-margins from 79.76% to 83.86%, on a year-over-year basis. As a result, the company reported an EPS of $0.03 for the quarter, up by $0.07 as compared to the preceding year. Analysts have stated that the earnings growth of the company is average, as compared to its peer group. This indicates that Halozyme has control over its market share. However, the earnings growth has mostly been influenced by exercising cost controls. Added to this, the revenues have also been affected by several one-time sales, during the quarter. The revenues for the 4Q2014 were 30.38 million, compared to $52.23 million during 4Q2015.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) lost 0.21% of its share value, during the March 7 session, to reach a close at $9.57, after having a trade volume of 2.53 million.

SHARE
Previous articleIllumina, Inc. (NASDAQ:ILMN) to Appoint New CEO After 17 Years
Next articleInvivo Therapeutics Holdings Corp (NASDAQ:NVIV) Reveals AIS Grade Improvement in Fifth Patient
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.